Skip to main content Back to Top
Advertisement

8/7/2020

Methocarbamol Tablets

Products Affected - Description

    • Robaxin oral tablet, Endo Pharmaceuticals, 500 mg, bottle, 100 count, NDC 52244-0429-10 - discontinued
    • Robaxin oral tablet, Endo Pharmaceuticals, 750 mg, bottle, 100 count, NDC 52244-0449-10 - discontinued
    • Methocarbamol oral tablet, Par Pharmaceuticals, 500 mg, bottle, 100 count, NDC 00603-4485-21 - discontinued
    • Methocarbamol oral tablet, Par Pharmaceuticals, 500 mg, bottle, 500 count, NDC 00603-4485-28 - discontinued
    • Methocarbamol oral tablet, Par Pharmaceuticals, 750 mg, bottle, 100 count, NDC 00603-4486-21 - discontinued
    • Methocarbamol oral tablet, Par Pharmaceuticals, 750 mg, bottle, 500 count, NDC 00603-4486-28 - discontinued
    • Methocarbamol oral tablet, Par Pharmaceuticals, 750 mg, bottle, 1000 count, NDC 00603-4486-32 - discontinued
    • Methocarbamol oral tablet, Virtus, 500 mg, bottle, 100 count, NDC 69543-0134-10 - discontinued
    • Methocarbamol oral tablet, Virtus, 500 mg, bottle, 500 count, NDC 69543-0134-50 - discontinued
    • Methocarbamol oral tablet, Virtus, 750 mg, bottle, 100 count, NDC 69543-0135-10 - discontinued
    • Methocarbamol oral tablet, Virtus, 750 mg, bottle, 500 count, NDC 69543-0135-50 - discontinued

Reason for the Shortage

    • Bayshore has methocarbamol tablets available.
    • Camber has methocarbamol tablets available.
    • Endo discontinued Robaxin tablets in January 2020.
    • Granules has methocarbamol tablets available.
    • Hikma is not actively marketing methocarbamol tablets.
    • Par discontinued methocarbamol tablets in July 2018.
    • Solco states the shortage was due to an active ingredient shortage.
    • Virtus discontinued methocarbamol tablets in June 2019.

Available Products

    • Methocarbamol oral tablet, Bayshore, 500 mg, bottle, 100 count, NDC 76385-0123-01
    • Methocarbamol oral tablet, Bayshore, 500 mg, bottle, 500 count, NDC 76385-0123-50
    • Methocarbamol oral tablet, Bayshore, 750 mg, bottle, 100 count, NDC 76385-0124-01
    • Methocarbamol oral tablet, Bayshore, 750 mg, bottle, 500 count, NDC 76385-0124-50
    • Methocarbamol oral tablet, Camber, 500 mg, bottle, 100 count, NDC 31722-0533-01
    • Methocarbamol oral tablet, Camber, 500 mg, bottle, 500 count, NDC 31722-0533-05
    • Methocarbamol oral tablet, Camber, 750 mg, bottle, 100 count, NDC 31722-0534-01
    • Methocarbamol oral tablet, Camber, 750 mg, bottle, 500 count, NDC 31722-0534-05
    • Methocarbamol oral tablet, Granules, 500 mg, bottle, 100 count, NDC 62207-0754-43
    • Methocarbamol oral tablet, Granules, 500 mg, bottle, 500 count, NDC 62207-0754-47
    • Methocarbamol oral tablet, Granules, 750 mg, bottle, 100 count, NDC 62207-0770-43
    • Methocarbamol oral tablet, Granules, 750 mg, bottle, 500 count, NDC 62207-0770-47
    • Methocarbamol oral tablet, Solco Healthcare US, 500 mg, bottle, 100 count, NDC 43547-0405-10
    • Methocarbamol oral tablet, Solco Healthcare US, 500 mg, bottle, 500 count, NDC 43547-0405-50
    • Methocarbamol oral tablet, Solco Healthcare US, 750 mg, bottle, 100 count, NDC 43547-0226-10
    • Methocarbamol oral tablet, Solco Healthcare US, 750 mg, bottle, 500 count, NDC 43547-0226-50

Updated

Updated August 7, 2020 by Leslie Jensen, PharmD, Drug Information Specialist. Created May 8, 2018 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2020, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins


ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.
ADVERTISEMENT